JP2013503134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503134A5 JP2013503134A5 JP2012526048A JP2012526048A JP2013503134A5 JP 2013503134 A5 JP2013503134 A5 JP 2013503134A5 JP 2012526048 A JP2012526048 A JP 2012526048A JP 2012526048 A JP2012526048 A JP 2012526048A JP 2013503134 A5 JP2013503134 A5 JP 2013503134A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- anhydrous crystalline
- crystalline form
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23743509P | 2009-08-27 | 2009-08-27 | |
| US61/237,435 | 2009-08-27 | ||
| PCT/EP2010/062420 WO2011023733A1 (en) | 2009-08-27 | 2010-08-25 | Anhydrate forms of a pyridine derivative |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015139845A Division JP6404186B2 (ja) | 2009-08-27 | 2015-07-13 | 無水形態のピリジン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013503134A JP2013503134A (ja) | 2013-01-31 |
| JP2013503134A5 true JP2013503134A5 (enExample) | 2013-09-19 |
Family
ID=42790943
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012526048A Pending JP2013503134A (ja) | 2009-08-27 | 2010-08-25 | 無水形態のピリジン誘導体 |
| JP2015139845A Active JP6404186B2 (ja) | 2009-08-27 | 2015-07-13 | 無水形態のピリジン誘導体 |
| JP2017114602A Pending JP2017193564A (ja) | 2009-08-27 | 2017-06-09 | 無水形態のピリジン誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015139845A Active JP6404186B2 (ja) | 2009-08-27 | 2015-07-13 | 無水形態のピリジン誘導体 |
| JP2017114602A Pending JP2017193564A (ja) | 2009-08-27 | 2017-06-09 | 無水形態のピリジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8796269B2 (enExample) |
| EP (1) | EP2470545B1 (enExample) |
| JP (3) | JP2013503134A (enExample) |
| KR (1) | KR20120056258A (enExample) |
| CN (1) | CN102639536B (enExample) |
| AU (1) | AU2010288502B2 (enExample) |
| CA (1) | CA2772168C (enExample) |
| DK (1) | DK2470545T3 (enExample) |
| EA (1) | EA021411B1 (enExample) |
| ES (1) | ES2440938T3 (enExample) |
| IL (1) | IL217922A (enExample) |
| IN (1) | IN2012DN01292A (enExample) |
| MX (1) | MX2012002369A (enExample) |
| PL (1) | PL2470545T3 (enExample) |
| SG (1) | SG178231A1 (enExample) |
| WO (1) | WO2011023733A1 (enExample) |
| ZA (1) | ZA201200812B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010288502B2 (en) * | 2009-08-27 | 2013-12-12 | KaNDy Therapeutics Ltd. | Anhydrate forms of a pyridine derivative |
| EP3915560A1 (en) * | 2014-06-25 | 2021-12-01 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
| HUE047732T2 (hu) | 2015-05-18 | 2020-05-28 | Nerre Therapeutics Ltd | NK-1/NK-3 receptor antagonista vértolulások kezeléséhez |
| US11028099B2 (en) * | 2016-12-15 | 2021-06-08 | Glaxosmithkline Intellectual Property Development Limited | NRF2 activators |
| PL3765024T3 (pl) | 2018-03-14 | 2024-08-05 | KaNDy Therapeutics Limited | <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div> |
| WO2021030335A1 (en) * | 2019-08-12 | 2021-02-18 | Millendo Therapeutics, Inc. | A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof |
| JP7673064B2 (ja) | 2019-11-15 | 2025-05-08 | カンディー セラピューティクス リミテッド | Ｎｔ－８１４の重要な中間体である６－クロロ－４－（４－フルオロ－２－メチルフェニル）ピリジン－３－アミンを作製するための新規な化学的方法 |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| WO2025242584A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | A stable soft gelatin capsule formulation for elinzanetant |
| TW202604529A (zh) * | 2024-06-18 | 2026-02-01 | 瑞士商拜耳保健消費品股份有限公司 | 用於製造依林奈坦(elinzanetant)前驅物之改良方法 |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1394150T3 (da) * | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| PL378404A1 (pl) * | 2003-01-31 | 2006-04-03 | F. Hoffmann-La Roche Ag | Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu |
| HRP20070471T3 (hr) * | 2003-07-03 | 2007-11-30 | F. Hoffmann - La Roche Ag | Dvojni nk1/nk3 antagonisti za liječenje shizofrenije |
| US7683056B2 (en) * | 2005-09-09 | 2010-03-23 | Glaxosmithkline Llc | Pyridine derivatives and their use in the treatment of psychotic disorders |
| KR20100101051A (ko) * | 2007-12-11 | 2010-09-16 | 씨아이피엘에이 엘티디. | 조피클론 결정성 다형체, 이들의 제조 공정 및 이들의 약제 조성물 |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| AU2010288502B2 (en) * | 2009-08-27 | 2013-12-12 | KaNDy Therapeutics Ltd. | Anhydrate forms of a pyridine derivative |
| JP6342662B2 (ja) * | 2014-01-29 | 2018-06-13 | 京セラ株式会社 | ドリルおよびそれを用いた切削加工物の製造方法 |
-
2010
- 2010-08-25 AU AU2010288502A patent/AU2010288502B2/en active Active
- 2010-08-25 IN IN1292DEN2012 patent/IN2012DN01292A/en unknown
- 2010-08-25 JP JP2012526048A patent/JP2013503134A/ja active Pending
- 2010-08-25 KR KR1020127004865A patent/KR20120056258A/ko not_active Ceased
- 2010-08-25 SG SG2012007464A patent/SG178231A1/en unknown
- 2010-08-25 EA EA201270302A patent/EA021411B1/ru not_active IP Right Cessation
- 2010-08-25 MX MX2012002369A patent/MX2012002369A/es active IP Right Grant
- 2010-08-25 CA CA2772168A patent/CA2772168C/en active Active
- 2010-08-25 PL PL10747619T patent/PL2470545T3/pl unknown
- 2010-08-25 CN CN201080037918.3A patent/CN102639536B/zh active Active
- 2010-08-25 ES ES10747619.4T patent/ES2440938T3/es active Active
- 2010-08-25 US US13/389,525 patent/US8796269B2/en active Active
- 2010-08-25 EP EP10747619.4A patent/EP2470545B1/en active Active
- 2010-08-25 WO PCT/EP2010/062420 patent/WO2011023733A1/en not_active Ceased
- 2010-08-25 DK DK10747619.4T patent/DK2470545T3/da active
-
2012
- 2012-02-02 IL IL217922A patent/IL217922A/en active IP Right Grant
- 2012-02-02 ZA ZA2012/00812A patent/ZA201200812B/en unknown
-
2015
- 2015-07-13 JP JP2015139845A patent/JP6404186B2/ja active Active
-
2017
- 2017-06-09 JP JP2017114602A patent/JP2017193564A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
| JP2010501519A5 (enExample) | ||
| IL214086A (en) | Malt salt of n- {4 - {[7,6- bis (methyllaxy) quinoline-4-yl] oxy} phenyl) - n- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms for cancer treatment | |
| FI2534153T4 (fi) | 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja | |
| JP2015010091A5 (enExample) | ||
| JP2011168587A5 (enExample) | ||
| JP2014501282A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JP2010516681A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| JP2020511467A5 (enExample) | ||
| JP2009537498A5 (enExample) | ||
| CA2729266A1 (en) | A novel molecular sieve composition emm-13, a method of making and a process of using the same | |
| JP2011529440A5 (enExample) | ||
| JP2015522589A5 (enExample) | ||
| RU2015106137A (ru) | Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения | |
| JP2012533550A5 (enExample) | ||
| JP2020536893A5 (enExample) | ||
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| JP2013501041A5 (enExample) | ||
| JP2015522037A5 (enExample) | ||
| JP2016000739A5 (enExample) | ||
| JP2015516425A5 (enExample) | ||
| RU2018103172A (ru) | Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона | |
| RU2017134709A (ru) | П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения |